Aloxi is a drug owned by Helsinn Healthcare Sa. It is protected by 28 US drug patents filed from 2013 to 2017 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 30, 2024. Details of Aloxi's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Aloxi's patents.

Latest Legal Activities on Aloxi's Patents

Given below is the list of recent legal activities going on the following patents of Aloxi.

Activity	Date	Patent Number
Today's Legal Activities
Maintenance Fee Reminder Mailed Critical	27 May, 2024	US9457020
Payment of Maintenance Fee, 8th Year, Large Entity	22 Feb, 2023	US9125905 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	16 Nov, 2022	US9066980 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	16 Nov, 2022	US7960424 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	20 Oct, 2022	US7947724 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	20 Oct, 2022	US7947725 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	20 May, 2021	US8598218 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	20 May, 2021	US8598219 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity	21 Jan, 2021	US8518981 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity	17 Mar, 2020	US9457020

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Aloxi and ongoing litigations to help you estimate the early arrival of Aloxi generic.

Aloxi's Litigations

Aloxi been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 02, 2014, against patent number US8598219. The petitioner Accord Healthcare, Inc., challenged the validity of this patent, with Helsinn Healthcare S.A. as the respondent. Click below to track the latest information on how companies are challenging Aloxi's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US9173942	February, 2016	Terminated-Denied (17 Aug, 2016)	Helsinn Healthcare S.A.	Dr. Reddy's Laboratories, Ltd
US8729094	July, 2015	Terminated-Denied (14 Oct, 2015)	Helsinn Healthcare S.A.	Dr. Reddy's Laboratories, Ltd
US8729094	July, 2015	Terminated-Denied (14 Oct, 2015)	Helsinn Healthcare S.A.	Dr. Reddy's Laboratories, Ltd.
US8598219	September, 2014	Terminated-Denied (24 Nov, 2014)	Helsinn Healthcare S.A.	Accord Healthcare, Inc.

FDA has granted some exclusivities to Aloxi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Aloxi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Aloxi.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Aloxi's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Aloxi's generic, the next section provides detailed information on ongoing and past EP oppositions related to Aloxi patents.

Aloxi's Oppositions Filed in EPO

Aloxi has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 08, 2009, by Tecnimede Sociedade Tecnico-Medicinal, S.A.. This opposition was filed on patent number EP04706657A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP04706657A	Jul, 2009	DR REDDYS LABORATORIES (UK) LIMITED	Revoked
EP04706657A	Jul, 2009	White, Martin Paul	Revoked
EP04706657A	Jul, 2009	Tecnimede Sociedade Tecnico-Medicinal, S.A.	Revoked

US patents provide insights into the exclusivity only within the United States, but Aloxi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Aloxi's family patents as well as insights into ongoing legal events on those patents.

Aloxi's Family Patents

Aloxi has patent protection in a total of 40 countries. It's US patent count contributes only to 29.9% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Aloxi.

Full family tree

Generic Launch

About Aloxi

Aloxi is a drug owned by Helsinn Healthcare Sa. It is used for preventing nausea and vomiting caused by chemotherapy and postoperative procedures. Aloxi uses Palonosetron Hydrochloride as an active ingredient. Aloxi was launched by Helsinn Hlthcare in 2008.